• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    10/14/25 4:46:20 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email
    avtr-20251009
    false000172248200017224822025-10-092025-10-090001722482us-gaap:CommonStockMember2025-10-092025-10-09


    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): October 9, 2025
    avantorlogoa08.jpg
    Avantor, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware001-3891282-2758923
    (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
    Radnor Corporate Center, Building One, Suite 200
    100 Matsonford Road
    Radnor, Pennsylvania 19087
    (Address of principal executive offices, including zip code)
    (610) 386-1700
    (Registrant’s telephone number, including area code)
    Not Applicable
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:



    Title of each classTrading SymbolExchange on which registered
    Common Stock, $0.01 par valueAVTRNew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 1.01. Entry into a Material Definitive Agreement.
    Senior Secured Credit Facilities Amendment
    On October 9, 2025, Avantor Funding, Inc. (the “Borrower”), a wholly-owned subsidiary of Avantor, Inc. (the “Company”), certain other subsidiaries of the Company, the lenders party thereto, and Goldman Sachs Bank USA, as administrative agent and collateral agent, entered into Amendment No. 14 to Credit Agreement (the “Amendment”), which amends the Credit Agreement dated as of November 21, 2017, as previously amended from time to time (the “Credit Agreement” and, as amended by the Amendment, the “Amended Credit Agreement”).
    The Amendment, among other things: (i) provides for replacement revolving credit commitments in the amount of $975 million and establishes an additional $425 million of incremental revolving credit commitments, resulting in an aggregate of $1.4 billion in revolving credit commitments under the Amended Credit Agreement (the “RCF”); (ii) establishes a new €400 million tranche of Incremental Euro Term A Loans (the “TLA”); and (iii) establishes a new €550 million tranche of Incremental B-6 Euro Term Loans (the “TLB” and, together with the RCF and the TLA, the “New Credit Facilities”).
    The Amendment also extends the maturity date of the RCF to October 9, 2030. The maturity date of the TLB is October 9, 2032 and the maturity date of the TLA is October 9, 2030.
    The proceeds of the New Credit Facilities will be used to repay and/or refinance in whole or in part certain existing senior secured indebtedness, including under the Credit Agreement, the A/R Facility (as defined below), and the remaining outstanding €250 million in aggregate principal amount of the Notes (as defined below), to pay related fees and expenses, and to provide additional liquidity and funding for the ongoing business needs of the Company and its subsidiaries.
    The New Credit Facilities bear interest at a benchmark rate plus an applicable margin. The applicable margin under the RCF and the TLA is determined based on a leverage-based pricing grid set forth in the Amended Credit Agreement. Unused RCF commitments accrue a commitment fee as provided for therein. The applicable margin for the TLB is 2.50% plus the benchmark rate, as set forth in the Amended Credit Agreement. The Borrower also pays customary letter of credit, agency, and administrative fees.
    The Borrower’s obligations under the Amended Credit Agreement are unconditionally guaranteed by substantially all of its wholly owned domestic subsidiaries. The Company is not a guarantor, although Vail Holdco Sub LLC, a wholly owned subsidiary of the Company and the parent of the Borrower, is a guarantor. The obligations of the Borrower and guarantors are secured by a security interest in substantially all of the assets of the Borrower and each guarantor, in each case, subject to permitted liens and other customary exceptions and limitations.
    The Amended Credit Agreement contains customary affirmative and negative covenants, including, among other things, covenants that restrict or limit the ability of the Borrower and guarantors to incur indebtedness, grant liens, make investments, consummate mergers and asset sales, prepay junior indebtedness, and make restricted payments, in each case, subject to certain negotiated exceptions, baskets and thresholds. The Amended Credit Agreement also includes customary events of default, including non-payment of principal, interest or other amounts due thereunder, breaches of covenants, inaccuracy of representations and warranties, cross-defaults to certain other material indebtedness, bankruptcy and insolvency events, the entry of material judgments, certain ERISA events and the invalidity of material guarantees or security interests.



    A copy of the Amendment is included as Exhibit 10.1 hereto and is incorporated by reference herein. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement.
    Item 1.02. Termination of a Material Agreement.
    PNC A/R Facility Termination
    On October 9, 2025 (the “Termination Date”), certain subsidiaries of the Company entered into an Assignment and Termination Agreement (the “Termination Agreement”) with PNC Bank, National Association (the “Bank”), as administrator, purchaser agent, related committed purchaser, LC bank and LC participant, and Wells Fargo Bank, National Association, as purchaser agent, related committed purchaser and LC participant, pursuant to which the up to $300 million accounts receivable securitization facility established on March 27, 2020 (the “A/R Facility”) was repaid in full and terminated. On the Termination Date, approximately $208 million was outstanding under the A/R Facility.
    Under the Termination Agreement, all outstanding amounts under the A/R Facility were repaid in full and all other obligations thereunder were satisfied. In connection with the termination of the A/R Facility, among other things, the applicable subsidiaries of the Company repurchased from PNC all receivables and related rights previously sold under the Receivables Purchase Agreement dated March 27, 2020. The A/R Facility and all related transaction documents and security were terminated and released.
    Item 2.03. Creation of a Direct Financial Obligation under an Off-Balance Sheet Arrangement of Registrant.
    The information set forth in Item 1.01 is incorporated into this Item 2.03 by reference.
    Item 8.01. Other Events.
    On August 29, 2025, the Borrower redeemed €400 million in aggregate principal amount outstanding of its 2.625% Senior First Lien Notes due 2025 (the “Notes”) at a redemption price equal to 100% of the principal amount of the Notes redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. On October 10, 2025, the Borrower redeemed the remaining outstanding €250 million in aggregate principal amount of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.
    Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits.
    Exhibit No.Description
    4.1
    Amendment No. 14 to Credit Agreement, dated as of October 9, 2025, among Vail Holdco Sub LLC, as holdings, Avantor Funding, Inc., as the borrower, each of the guarantors party thereto, Goldman Sachs Bank USA, as administrative agent and collateral agent, and the lenders and issuers from time to time party thereto.
    4.2The cover page from this Current Report on Form 8-K, formatted in Inline XBRL



    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Avantor, Inc.
    Date: October 14, 2025By:/s/ Steven Eck
    Name:Steven Eck
    Title:Senior Vice President and Chief Accounting Officer

    Get the next $AVTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    8/1/2025Buy → Hold
    Jefferies
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    8/28/2024$30.00Overweight
    Wells Fargo
    7/10/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    More analyst ratings

    $AVTR
    SEC Filings

    View All

    Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    10/14/25 4:46:20 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    10/14/25 8:37:42 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    10/3/25 8:35:42 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avantor downgraded by Jefferies

    Jefferies downgraded Avantor from Buy to Hold

    8/1/25 1:45:47 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Goldman with a new price target

    Goldman downgraded Avantor from Buy to Neutral and set a new price target of $14.00

    4/29/25 8:05:35 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by TD Cowen with a new price target

    TD Cowen downgraded Avantor from Buy to Hold and set a new price target of $15.50

    4/28/25 8:32:10 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T was granted 8,736 shares (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/7/25 5:04:57 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Lucier Gregory T

    3 - Avantor, Inc. (0001722482) (Issuer)

    10/7/25 5:02:06 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP, Bioscience Production Gourdier Benoit covered exercise/tax liability with 1,264 shares, decreasing direct ownership by 0.53% to 235,684 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/3/25 4:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® and BlueWhale Bio Partner to Accelerate CAR-T Manufacturing with Breakthrough Cell Activation and Expansion Technology

    RADNOR, Pa. and PHILADELPHIA, Oct. 15, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced a strategic partnership with BlueWhale Bio, a commercial-stage company dedicated to transforming immune cell therapy manufacturing and addressing the unmet need in CAR-T production by streamlining manufacturing, reducing variability, and shortening time-to-patient. The partnership combines Avantor's bioprocessing and custom ancillary-reagent manufacturing capabilities with BlueWhale Bio's Synecta™ cell-derived nanoparticle (CDNP) platform, which mimics

    10/15/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Announces Board Chairman Transition

    Gregory L. Summe to Serve as Next Chairman of the Board Beginning on January 1, 2026 Jonathan Peacock to Step Down After Nearly Nine Years of Dedicated Service to the Board RADNOR, Pa., Oct. 13, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Gregory L. Summe, current independent director, will serve as the Company's next Chairman of the Board, beginning January 1, 2026. Jonathan Peacock has informed the Board of his decision to step down as Chairman and as a director at the end of 2025, after nearly nine years of dedicated service to

    10/13/25 4:05:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Gregory T. Lucier to its Board of Directors

    Brings more than three decades of leadership experience in the life sciences industry RADNOR, Pa., Oct. 3, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Gregory T. Lucier to its Board of Directors. Mr. Lucier brings significant experience and broad expertise across the healthcare landscape to the Avantor Board. He founded and serves as Executive Chairman and CEO of Corza Medical, a leading global manufact

    10/3/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $1,256,000 worth of shares (100,000 units at $12.56) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/22/25 4:15:22 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $375,000 worth of shares (30,000 units at $12.50) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/27/25 4:58:03 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $253,000 worth of shares (20,000 units at $12.65) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/22/25 5:37:34 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® to Host Third Quarter 2025 Earnings Call on Wednesday, October 29, 2025

    RADNOR, Pa., Oct. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, October 29, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global

    10/1/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Second Quarter 2025 Results

    Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv

    8/1/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Announces Emmanuel Ligner as Next President and CEO

    Seasoned Executive with Proven Track Record of Value Creation in Life Sciences RADNOR, Pa., July 21, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that it has named Emmanuel Ligner, President and Chief Executive Officer, effective August 18, 2025. Mr. Ligner succeeds Michael Stubblefield, who will, as previously announced, step down from his role as Director, President and Chief Executive Officer upon Mr. Ligner's appointme

    7/21/25 7:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Gregory T. Lucier to its Board of Directors

    Brings more than three decades of leadership experience in the life sciences industry RADNOR, Pa., Oct. 3, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Gregory T. Lucier to its Board of Directors. Mr. Lucier brings significant experience and broad expertise across the healthcare landscape to the Avantor Board. He founded and serves as Executive Chairman and CEO of Corza Medical, a leading global manufact

    10/3/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

    RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform

    11/6/24 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials